SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Vyome Holdings, Inc
Date: May 7, 2025 · CIK: 0001427570 · Accession: 0000000000-25-004824

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
May 7, 2025
Author
Division of
Form
UPLOAD
Company
Vyome Holdings, Inc

Letter

Re: ReShape Lifesciences Inc. Draft Registration Statement on Form S-3 Submitted May 2, 2025 CIK No. 0001427570 Dear Paul F. Hickey:

May 7, 2025

Paul F. Hickey Chief Executive Officer ReShape Lifesciences Inc. 18 Technology Dr., Suite 110 Irvine, CA 92618

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Brett Hanson, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 7, 2025

Paul F. Hickey
Chief Executive Officer
ReShape Lifesciences Inc.
18 Technology Dr., Suite 110
Irvine, CA 92618

 Re: ReShape Lifesciences Inc.
 Draft Registration Statement on Form S-3
 Submitted May 2, 2025
 CIK No. 0001427570
Dear Paul F. Hickey:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Doris Stacey Gama at 202-551-3188 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Brett Hanson, Esq.
</TEXT>
</DOCUMENT>